HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $300 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Biogen (NASDAQ:BIIB) and maintained a $300 price target.
May 23, 2024 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Biogen and maintained a $300 price target.
The reiteration of a Buy rating and a maintained price target of $300 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100